We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Genomic Signatures in Luminal Breast Cancer.
- Authors
Puppe, Julian; Seifert, Tabea; Eichler, Christian; Pilch, Henryk; Mallmann, Peter; Malter, Wolfram
- Abstract
Background: Breast cancer is a very heterogeneous disease and luminal breast carcinomas represent the hormone receptor-positive tumors among all breast cancer subtypes. In this context, multigene signatures were developed to gain further prognostic and predictive information beyond clinical parameters and traditional immunohistochemical markers. Summary: For early breast cancer patients these molecular tools can guide clinicians to decide on the extension of endocrine therapy to avoid over- and undertreatment by adjuvant chemotherapy. Beside the predictive and prognostic value, a few genomic tests are also able to provide intrinsic subtype classification. In this review, we compare the most frequently used and commercially available molecular tests (OncotypeDX®, MammaPrint®, Prosigna®, EndoPredict®, and Breast Cancer IndexSM). Moreover, we discuss the clinical utility of molecular profiling for advanced breast cancer of the luminal subtype. Key Messages: Multigene assays can help to de-escalate systemic therapy in early-stage breast cancer. Only the Oncotype DX® and MammaPrint®test are validated by entirely prospective and randomized phase 3 trials. More clinical evidence is needed to support the use of genomic tests in node-positive disease. Recent developments in high-throughput sequencing technology will provide further insights to understand the heterogeneity of luminal breast cancers in early-stage and metastatic disease.
- Subjects
BREAST cancer prognosis; BREAST tumors; GENE expression; IMMUNOHISTOCHEMISTRY; TUMOR markers; GENOMICS
- Publication
Breast Care, 2020, Vol 15, Issue 4, p355
- ISSN
1661-3791
- Publication type
Article
- DOI
10.1159/000509846